Ethiodized Oil

Q1 2024 revenue Quarterly activity Revenue: €194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was temporarily impacted by the reform of the supply of contrast products in France Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 April 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its revenue for the first fiscal quarter. At 31 March 2024, the Group’s sales totalled €194.3m, up 7.6% compared with the same period in 2023. Given an unfavourable foreign exchange effect of €2.2m, largely linked to Asian currencies, revenue at CER1 was up 8.8% over the period. Geographical breakdown of consolidated Group revenue (IFRS) In millions of euros,at 31 March 2024Q1 2023*Q1 2024% changeQ1 2024At CER1% changeSales in EMEA89.083.9-5.8%83.6-6.2%Sales in the Americas47.557.4+21%57.0+20.1%Sales in Asia44.152.9+20%55.9+26.8%Total180.6194.3+7.6%196.5+8.8% *Revenue for Q1 2023 has been restated to include Intrasense, which has been consolidated since 1 January 2023. In the EMEA region, the Group generated revenue of €83.9m in the first quarter, down 5.8% (-6.2% at CER) mainly owing to the dip in sales volumes in France. This trend stems directly from the implementation on 1 March 2024 of the reform of the supply circuit for contrast products, which caused difficulties in order intakes with radiologists. The Group expects to largely catch up on the resulting delays in sales in the second quarter of 2024. In the Americas, sales totalled €57.4m, up 21.0% over the period (+20.1% at CER). Sales caught up strongly for the second consecutive quarter following the return to historic production levels at the Raleigh site in North Carolina. Group revenue in Asia was €52.9m, with continued strong growth momentum (+20%) driven by the performances of China, South Korea and Japan. The total includes a negative currency effect (-€3.0m) linked in particular to the further depreciation of the yen. At CER, sales in Asia rose 26.8% in first-quarter 2024, confirming the Group’s ambitions in this region. Breakdown of consolidated Group revenue (IFRS) by activity In millions of euros,at 31 March 2024Q1 2023*Q1 2024% changeQ1 2024At CER1% changeDiagnostic Imaging 160.8173.6+7.9%175.5+9.1%MRI60.758.2-4.1%58.4-3.7%X-ray100.2115.4+15.2%117.1+16.9%Interventional Imaging19.820.7+4.4%21.0+6.1%Total180.6194.3+7.6%196.5+8.8% 1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.*Revenue for Q1 2023 has been restated to include Intrasense, which has been consolidated since 1 January 2023. Diagnostic Imaging revenue increased 7.9% in Q1 2024 (+9.1% at CER) to €173.6m. MRI activity was down 3.7% at CER. This decline resulted from the postponement of several substantial orders in the MRI franchise (Dotarem® / EluciremTM) in France, all of which will be booked in the second quarter of 2024.X-ray revenue increased 16.9% at CER over the period, a remarkable increase driven by all the division’s products, particularly Xenetix®. In Interventional Imaging, revenue rose 6.1% at CER in Q1 2024 on continued favourable momentum for Lipiodol®, fuelled by volumes and prices alike. All financial targets confirmed for 2024 The highly positive trend overall at the start of the year boosts Guerbet’s confidence for the full year. In a buoyant contrast products market, Group business will be bolstered by the ramp-up of the MRI franchise, growth in Optiray® sales, and continued favourable momentum for Lipiodol®. At the same time, operating profitability will benefit from the change in the product mix and the continued rise in prices, while cash generation will improve considerably, particularly as inventory levels return to normal. Given these circumstances, Guerbet is confirming its forecast of sales growth of over 8% in 2024 like-for-like and at CER and expects its adjusted EBITDA margin rate to exceed that of 2021 (14.4%). Free cash flow is expected to be in positive territory for the full year. Next events : Annual Shareholders' Meeting for fiscal year 202324 May 2024 Publication of 1st half 2024 revenue 25 July 2024 after market close About GuerbetAt Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 97 years, with more than 2,920 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023. Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group’s activities can be found in Chapter 4.9 “Risk factors” of the Group’s Universal Registration Document filed with the AMF (French financial markets authority) under number D.24-0224 on April 3, 2024, available on the Group’s website (www.guerbet.com). 1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.2 Restated EBITDA margin rate : excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model. Attachment CP CA T1 2024_VFinale EN

来源：国家市场总局  整理：wangxinglai20042024年03月20日，国家市场总局发布公告，江西祥宇医药有限公司因销售碘化油原料药行为涉嫌违反修改前《中华人民共和国反垄断法》相关规定，被处罚超过156万元。通知原文  01 案件来源及调查经过经查，当事人江西祥宇医药有限公司主要从事药品销售业务，碘化油原料药系当事人经营产品之一。2016年6月至2020年3月期间，当事人滥用中国碘化油原料药销售市场的支配地位，实施了以不公平的高价销售原料药的垄断行为。1.当事人市场份额超过50%，可推定具有市场支配地位：经查询，目前持有登记号为A状态的碘化油原料药生产企业有2家，分别为湖北美林药业有限公司、上海万巷制药有限公司，国药集团中联药业有限公司持有批准文号但未开展关联审评登记，具体登记信息如下：其中，上海万巷由上海万代股东共同出资成立，2016年12月因政府产业规划调整等原因，上海万代被上海万巷吸收合并，碘化油原料药业务从上海万代转入上海万巷，因此上海万巷与上海万代紧密联系，以下统称两家公司为上海万巷。中联药业长期不生产碘化油原料药，2016年10月与湖北美林药业有限公司签订协议，将碘化油原料药批文和生产技术转让至湖北美林。涉案期间湖北美林没有完成碘化油原料药批文转让手续，也没有进行制剂关联审评审批，未实际生产碘化油原料药。因此，上海万巷是国内唯一生产碘化油原料药的企业。 2015年12月，当事人与上海万巷签订《项目合作协议》， 约定由上海万巷向当事人供应碘化油原料药。2016年6月至2020年3月期间，上海万巷共对外销售碘化油原料药***公 斤，绝大部分销售给了当事人。当事人从上海万巷购买碘化油原料药后，将原料药全部销售给了国内唯一一家碘化油注 射液生产企业烟台鲁银药业有限公司。 经统计，2016年6—12月、2017年、2018年、2019年、 2020年 1—3 月，当事人在中国碘化油原料药销售市场的市场份额分别为100%、85.8%、91.7%、100%、100%。 根据修改前的《反垄断法》第十九条的规定，可推定当事人在中国碘化油原料药销售市场上具有支配地位。 2.当事人具有很强的市场控制能力：当事人通过与上海万巷签订《项目合作协议》，并从上海万巷大量购买碘化油原料药，基本控制了上海万巷的原料药货源，具有控制碘化 油原料药销售价格、销售数量等关键交易条件能力。 3.下游制剂生产企业对当事人依赖程度很高：碘化油原料药是生产碘化油注射液的核心原材料，烟台鲁银在原料药采购上高度依赖当事人。此外，当事人有较为成熟的碘化油注射液销售团队，烟台鲁银向当事人购买原料药，可以同时获得销售推广服务，从而销售出更多的碘化油注射液。4.其他经营者进入销售市场难度较大：当事人通过与上海万巷签订协议等方式事实上控制了中国碘化油原料药的销售渠道，其他经营者想要进入碘化油原料药销售市场只能寻找新的原料药生产商。湖北美林在涉案期间没有生产过碘化油原料药，因注册报批流程、技术稳定性等原因，湖北美林短期内无法生产出满足制剂生产企业需要的碘化油原料药。因此，其他经营者进入该市场开展销售具有较大的难度。02 行政处罚依据和决定2022年6月24日，全国人大常委会通过《关于修改〈中 华人民共和国反垄断法〉的决定》，自2022年8月1日起 施行。《中华人民共和国行政处罚法》第三十七条规定：“实 施行政处罚，适用违法行为发生时的法律、法规、规章的规 定。但是，作出行政处罚决定时，法律、法规、规章已被修 改或者废止，且新的规定处罚较轻或者不认为是违法的，适用新的规定。本案涉案行为发生于2016年6月至2020年3月，且修改后的《反垄断法》对此不存在处罚较轻或者不认为是违法的情况，故本案应适用修改前的《反垄断法》进行定性、处罚。本局决定责令当事人停止违法行为，处当事人2019年销售额4%的罚款 ， 计人民币1,563,625.54元。